To gain a panoramic view of Nevro's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

The $5.85 per share consideration represents a 27% premium to the 90-day volume-weighted average price of $4.61, a 38% premium to the 30-day VWAP of $4.23, and a 17% premium to Nevro’s closing ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all ... accessories and unique surgical instruments used in spinal, orthopedic and neurosurgical ...

Nevro (NVRO) could be a solid choice for investors ... as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its neuromodulation platforms for treating chronic pain. The all-cash deal comes ...

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a definitive agreement for Globus Medical to acquire all its ...

In a report released on February 7, Nathan Treybeck from Wells Fargo maintained a Hold rating on Nevro Corp (NVRO – Research Report), with a price target of $5.85. The company’s shares closed ...